- Researchers in the U.K. have evaluated additional findings about the immune-system impacts of Lemtrada®(alemtuzimab, Genzyme, a Sanofi Company), a disease-modifying therapy for treating people with relapsing MS.
- The team used data from phase 3 clinical trials submitted to the European Medicines Agency during the drug’s successful approval process. Some of this data was previously reported at medical meetings and in Lemtrada’s prescribing information.
- Among their findings, they report that Lemtrada caused long-term reduction of specific immune cells (memory B and T cells, including regulatory T cells). They also found…
Potrebbe interessarti anche
Agenzie del farmaco AISM Associazioni Blog Cannabis Cause CCSVI Cellule staminali definizione Diagnosi Dieta Diritto Disabilità Enti Estero Europa Eutanasia Farmaci Genetica Gravidanza inglese Istituzioni Microbioma News Omosessualità Ospedali Patologie Personaggi e Persone Ricerca Sintomi sociale Sport Vaccini